.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Covington
Teva
Cipla
Chinese Patent Office
Merck
Citi
Dow
US Army
Fuji

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,235,004

« Back to Dashboard

Which drugs does patent 6,235,004 protect, and when does it expire?


Patent 6,235,004 protects NORDITROPIN NORDIFLEX and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: 6,235,004

Title: Injection syringe
Abstract:The present invention provides an injection syringe comprises a housing including a holder for containing a cartridge of medicine, a piston rod with a non-circular cross-section having an outer thread, a piston rod drive, a one way coupling having an annular ring of internal ratchet notches, which annular ring can be integral with the housing, and a pawl having at least a pair of resilient arms each having a free end.
Inventor(s): Steenfeldt-Jensen; S.o slashed.ren (Hornb.ae butted.k, DK), Hansen; Steffen (Hiller.o slashed.d, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:09/429,677
Patent Claim Types:
see list of patent claims
Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-004Oct 1, 2004DISCNNoNo6,235,004► SubscribeY
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-005Oct 1, 2004DISCNNoNo6,235,004► SubscribeY
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-006Oct 1, 2004DISCNNoNo6,235,004► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,235,004

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark1998 00130Jan 30, 1998

Non-Orange Book Patents for Patent: 6,235,004

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,004,297 Injection syringe► Subscribe
RE43834Injection syringe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,235,004

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2214286► Subscribe
Portugal1003581► Subscribe
Poland191327► Subscribe
Norway20001559► Subscribe
Japan3270761► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Argus Health
McKinsey
AstraZeneca
Cantor Fitzgerald
Colorcon
Harvard Business School
Baxter
Queensland Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot